NONO

Across TCGA pan-cancer cohorts, NONO mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated NONO data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NONO mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NONO expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where NONO mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.380	0.974	.001	23	view →
HNSC	DFS	Quartile	All	0.333	0.855	.010	20	view →
LUAD	OS	Median	II,III,IV	0.812	0.452	.002	19	view →
LSCC	DFS	Median	II,III,IV	0.843	0.562	.006	15	view →
OV	DFS	Median	All	0.666	0.923	.040	8	view →
COAD	DFS	Median	II,III,IV	1.000	0.896	.047	6	view →
GBM	DFS	Median	All	0.335	0.208	.030	5	view →
CCRCC	DFS	Tertile	All	0.794	1.000	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NONO–PDAC (DFS)

Open the PDAC breakdown →